Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis
Background: Patients with relapsing-remitting multiple sclerosis (RRMS) may experience acute relapses that are nonresponsive (20-35%) to...
The Multiple Sclerosis at Home Access Program (MAHA): New Challenges for Those Living with Multiple Sclerosis and Significant Disability during the COVID-19 Pandemic
Background: Abundant evidence supports disparity in health care delivery for persons with disability. These disparities may be magnified...
Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire
Background: The validated physician-completed MSProDiscussTM tool facilitates physician-patient interaction in evaluating early signs of...
Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Background: Early treatment of multiple sclerosis (MS) and rapid onset of therapeutic effect provide long-term benefits on disease...